A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension
Phase of Trial: Phase III
Latest Information Update: 29 May 2018
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 02 Mar 2018 This trial has been discontinued in Italy.
- 18 Aug 2016 Planned End Date changed from 1 Dec 2022 to 1 Jan 2023.
- 18 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2021.